MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

(2020) Kari J. Kurppa et al.   CANCER CELL

Single-cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer

(2020) Josephine A Taverna et al.   CANCER RESEARCH

ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer

(2020) Naoko Okura et al.   CLINICAL CANCER RESEARCH

Unique Pro-Inflammatory Response of Macrophages during Apoptotic Cancer Cell Clearance

(2020) Veronica Mendoza-Reinoso et al.   Cells

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors

(2020) Justin A. Chen et al.   Journal of Thoracic Disease

Interaction with CD68 and regulation of GAS6 expression by endosialin in fibroblasts drives recruitment and polarization of macrophages in hepatocellular carcinoma

(2020) Fa Yang et al.   CANCER RESEARCH

Evidencing a pancreatic ductal adenocarcinoma subpopulation sensitive to the proteasome inhibitor Carfilzomib

(2020) Nicolas A Fraunhoffer et al.   CLINICAL CANCER RESEARCH

Genome‐wide cooperation of EMT transcription factor ZEB 1 with YAP and AP ‐1 in breast cancer

(2020) Nora Feldker et al.   EMBO JOURNAL

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment

(2020) Junnan Li et al.   Cancers

HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition

(2020) Qi Wang et al.   LUNG CANCER

The next tier of EGFR resistance mutations in lung cancer

(2020) Hannah L. Tumbrink et al.   ONCOGENE

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

(2020) Monique B. Nilsson et al.   Science Translational Medicine

1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells

(2020) Zhirong Jia et al.   Cell Death & Disease

AKT-induced lncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent Vimentin degradation

(2020) Han Tian et al.   Nature Communications

M2 macrophages reduce the effect of gefitinib by activating AKT / mTOR in gefitinib‐resistant cell lines HCC827 / GR

(2020) Fengqi Xiao et al.   Thoracic Cancer

Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC

(2020) Paul Giroud et al.   Frontiers in Immunology

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

(2020) Connor O’Leary et al.   Pharmaceuticals

Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients

(2020) Ilseon Hwang et al.   Journal of Translational Medicine

First‐in‐Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer

(2019) Aiwu Ruth He et al.   ONCOLOGIST

Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer

(2019) Canan Kasikara et al.   CANCER RESEARCH

Cancer upregulated gene (CUG)2 elevates YAP1 expression, leading to enhancement of epithelial-mesenchymal transition in human lung cancer cells

(2019) Sirichat Kaowinn et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells

(2019) Maureen Keller et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Gossypol overcomes EGFR-TKIs resistance in non-small cell lung cancer cells by targeting YAP/TAZ and EGFRL858R/T790M

(2019) Jian Xu et al.   BIOMEDICINE & PHARMACOTHERAPY

Gas6 Prevents Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells via Production of PGE2, PGD2 and Their Receptors

(2019) Jung et al.   Cells

Triple Therapy with MerTK and PD1 Inhibition plus Radiotherapy Promotes Abscopal Antitumor Immune Responses

(2019) Mauricio S. Caetano et al.   CLINICAL CANCER RESEARCH

A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis

(2019) Taha Azad et al.   ONCOGENE

STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers

(2019) Yi-Fang Chang et al.   BMC CANCER

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression

(2019) Shunli Peng et al.   Molecular Cancer

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lichen planus pemphigoides during therapy with tislelizumab and sitravatinib in a patient with metastatic lung cancer

(2019) Karolina Louisa Suzanna Kerkemeyer et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations

(2019) Riyaz Shah et al.   Clinical Lung Cancer

Who’s in charge here? Macrophage colony stimulating factor and granulocyte macrophage colony stimulating factor: Competing factors in macrophage polarization

(2019) Evan Trus et al.   CYTOKINE

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors

(2019) Ching-Yao Yang et al.   EUROPEAN JOURNAL OF CANCER

Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties

(2019) Jiahui Si et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Targeting histone deacetylase SIRT1 selectively eradicates EGFR TKI-resistant cancer stem cells via regulation of mitochondrial oxidative phosphorylation in lung adenocarcinoma

(2019) Jiangtao Sun et al.   NEOPLASIA

Targeted Next-Generation Sequencing Reveals a Novel Frameshift Mutation in the MERTK Gene in a Chinese Family with Retinitis Pigmentosa

(2018) Mu Yang et al.   Genetic Testing and Molecular Biomarkers

Phloretin attenuates mucus hypersecretion and airway inflammation induced by cigarette smoke

(2018) Hao Wang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

(2018) Aflah Roohullah et al.   INVESTIGATIONAL NEW DRUGS

Association between Genetic Variations of MERTK and Chronic Obstructive Pulmonary Disease in Koreans

(2018) Woo Jin Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Connective tissue growth factor induces renal fibrosis via epidermal growth factor receptor activation

(2018) Sandra Rayego-Mateos et al.   JOURNAL OF PATHOLOGY

The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis

(2018) B. R. Branchford et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Integrative gene ontology and network analysis of coronary artery disease associated genes suggests potential role of ErbB pathway gene EGFR

(2018) Madankumar Ghatge et al.   Molecular Medicine Reports

Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition

(2018) Juan Zhou et al.   ONCOLOGY REPORTS

Efferocytosis in atherosclerotic lesions: Malfunctioning regulatory pathways and control mechanisms

(2018) Amir Tajbakhsh et al.   PHARMACOLOGY & THERAPEUTICS

EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy

(2018) Hongwei Xia et al.   Cell Death & Disease

EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties

(2018) Yi Shao et al.   Oncology Letters

Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas

(2018) Ting-Fang Lee et al.   Scientific Reports

MerTK mediates STAT3–KRAS/SRC-signaling axis for glioma stem cell maintenance

(2018) Hyojin Eom et al.   Artificial Cells Nanomedicine and Biotechnology

Pemphigus—A Disease of Desmosome Dysfunction Caused by Multiple Mechanisms

(2018) Volker Spindler et al.   Frontiers in Immunology

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI

(2018) Chien-Hui Weng et al.   ONCOGENE

Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma

(2018) Jiale Wang et al.   CANCER BIOLOGY & THERAPY

Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation

(2018) Junsong Zhou et al.   Cell Communication and Signaling

Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells

(2017) Yinzhong Lu et al.   FASEB JOURNAL

MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure

(2017) Evangelos Triantafyllou et al.   GUT

MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat

(2017) Giovanni Musso et al.   HUMAN MOLECULAR GENETICS

MerTK Does Not Mediate Phagocytosis of Staphylococcus aureus but Attenuates Inflammation Induced by Staphylococcal Lipoteichoic Acid Through Blocking NF-κB Activation

(2017) Bing Zhang et al.   INFLAMMATION

Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis

(2017) Zuyao Yang et al.   INTERNATIONAL JOURNAL OF CANCER

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression

(2017) Canan Kasikara et al.   MOLECULAR CANCER RESEARCH

The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy

(2017) Céline Clémenson et al.   MOLECULAR CANCER THERAPEUTICS

Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer

(2017) Hatim Husain et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacoproteomic characterisation of human colon and rectal cancer

(2017) Martin Frejno et al.   Molecular Systems Biology

Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy

(2017) Qamar Ghafoor et al.   PATHOLOGY & ONCOLOGY RESEARCH

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

(2017) Anna Minchom et al.   PLoS One

Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies

(2017) Marie Schoumacher et al.   Current Oncology Reports

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition

(2017) Gongda Xue et al.   Oncotarget

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196

(2017) Natasha B. Leighl et al.   Oncotarget

PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression

(2017) Jai-Nien Tung et al.   Oncotarget

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

(2017) Kiyotaka Yoh et al.   Lancet Respiratory Medicine

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC

(2017) Elena Ghiso et al.   NEOPLASIA

Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”

(2017) Endang Purba et al.   Cells

Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells

(2017) An-Fu Lee et al.   PLoS One

Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non–Small-Cell Lung Cancer

(2016) Jae Joon Han et al.   Clinical Lung Cancer

Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy

(2016) Frank C. Cackowski et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy

(2016) Marka R. Crittenden et al.   Oncotarget

Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow

(2016) Younghun Jung et al.   Oncotarget

TAM Receptor Signaling in Immune Homeostasis

(2015) Carla V. Rothlin et al.   Annual Review of Immunology

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

(2015) D. Ercan et al.   CLINICAL CANCER RESEARCH

Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer

(2015) Jeffrey J. Tosoian et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation

(2015) Yosuke Togashi et al.   Journal of Thoracic Oncology

Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status

(2015) C. T. Cummings et al.   MOLECULAR CANCER THERAPEUTICS

EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src

(2015) Michael J Begley et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional screen identifies kinases driving prostate cancer visceral and bone metastasis

(2015) Claire M. Faltermeier et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src

(2015) Michael J Begley et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib

(2015) Shengzhi Xie et al.   Oncotarget

Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

(2015) Robert M. Jotte et al.   Cancer Medicine

Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application

(2015) Paolo Maione et al.   Therapeutic Advances in Medical Oncology

Mertk Deficiency Affects Macrophage Directional Migration via Disruption of Cytoskeletal Organization

(2015) Yong Tang et al.   PLoS One

Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer

(2015) Christopher T. Cummings et al.   Oncotarget

TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis

(2014) J. H. M. van der Meer et al.   BLOOD

Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion

(2014) Emelie Karnevi et al.   IMMUNOLOGY AND CELL BIOLOGY

Tyro3, Axl, and Mertk Receptor Signaling in Inflammatory Bowel Disease and Colitis-associated Cancer

(2014) Carla V. Rothlin et al.   INFLAMMATORY BOWEL DISEASES

Interdependent epidermal growth factor receptor signalling and trafficking

(2014) Sylwia Jones et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Receptor Tyrosine Kinases, TYRO3, AXL, and MER, Demonstrate Distinct Patterns and Complex Regulation of Ligand-induced Activation

(2014) Wen-I Tsou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TAM receptor deficiency affects adult hippocampal neurogenesis

(2014) Rui Ji et al.   METABOLIC BRAIN DISEASE

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

(2014) Magdalena Paolino et al.   NATURE

Diversification of TAM receptor tyrosine kinase function

(2014) Anna Zagórska et al.   NATURE IMMUNOLOGY

The cellular and molecular origin of tumor-associated macrophages

(2014) R. A. Franklin et al.   SCIENCE

Mutational Analysis of Key EGFR Pathway Genes in Chinese Breast Cancer Patients

(2013) Lin Tong et al.   Asian Pacific Journal of Cancer Prevention

TAM receptors in apoptotic cell clearance, autoimmunity, and cancer

(2013) Khanh-Quynh Nguyen et al.   AUTOIMMUNITY

Epidermal growth factor receptor targeting in cancer: A review of trends and strategies

(2013) Chetan Yewale et al.   BIOMATERIALS

TAM receptor tyrosine kinases: Expression, disease and oncogenesis in the central nervous system

(2013) Angela M. Pierce et al.   BRAIN RESEARCH

Molecular Pathways: MERTK Signaling in Cancer

(2013) C. T. Cummings et al.   CLINICAL CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

UNC1062, a new and potent Mer inhibitor

(2013) Jing Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis

(2013) Rebecca S. Cook et al.   JOURNAL OF CLINICAL INVESTIGATION

MERTK receptor tyrosine kinase is a therapeutic target in melanoma

(2013) Jennifer Schlegel et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors

(2013) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors

(2013) Weihe Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?

(2013) L. M. Coussens et al.   SCIENCE

Biology of the TAM Receptors

(2013) G. Lemke   Cold Spring Harbor Perspectives in Biology

Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia

(2013) L N Brandao et al.   Blood Cancer Journal

The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment

(2013) Takamitsu Sasaki et al.   Biomed Research International

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Loss of Epidermal Growth Factor Receptor in Vascular Smooth Muscle Cells and Cardiomyocytes Causes Arterial Hypotension and Cardiac Hypertrophy

(2012) Barbara Schreier et al.   HYPERTENSION

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer

(2012) R M A Linger et al.   ONCOGENE

Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme

(2012) Y Wang et al.   ONCOGENE

Differential macrophage programming in the tumor microenvironment

(2012) Brian Ruffell et al.   TRENDS IN IMMUNOLOGY

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

(2011) H.- T. Arkenau et al.   ANNALS OF ONCOLOGY

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

(2011) A. I. Daud et al.   CLINICAL CANCER RESEARCH

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

(2011) G. R. Oxnard et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations

(2011) Ning Lv et al.   Diagnostic Pathology

Galectin-3 is a new MerTK-specific eat-me signal

(2011) Nora B. Caberoy et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)

(2011) Carl R. Illig et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting Axl and Mer Kinases in Cancer

(2011) A. Verma et al.   MOLECULAR CANCER THERAPEUTICS

A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells

(2011) Kim J. Png et al.   NATURE

Alteration in NFKBIA and EGFR in Glioblastoma Multiforme

(2011) Ricardo J. Komotar et al.   NEUROSURGERY

Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology

(2011) A E J Rogers et al.   ONCOGENE

Phase I trial of SU14813 in patients with advanced solid malignancies

(2010) W. Fiedler et al.   ANNALS OF ONCOLOGY

Autoimmunity and the Clearance of Dead Cells

(2010) Shigekazu Nagata et al.   CELL

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis

(2010) Nora B Caberoy et al.   EMBO JOURNAL

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors

(2010) Rachel MA Linger et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Comprehensive Mapping of the Human Kinome to Epidermal Growth Factor Receptor Signaling

(2010) Kakajan Komurov et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

(2009) Tetsuya Mitsudomi et al.   FEBS Journal

Generation and validation of mice carrying a conditional allele of the epidermal growth factor receptor

(2009) Tang-Cheng Lee et al.   GENESIS